The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study
Open accessAbstract
SUMMARY Background. For young, peanut-allergic children, dietary avoidance is the current standard of care. We evaluated whether peanut oral immunotherapy (PnOIT) can induce desensitization (an increased allergic reaction threshold while on therapy) and/or remission (a state of nonresponsiveness following discontinuation of immunotherapy) in this population. Methods. A randomized, double-blind, placebo-controlled study was conducted in 5 US centers among children (ages 12–<48 months), reactive to ≤500 mg peanut protein during double-blind, placebo-controlled food challenge (DBPCFC). Participants were computer-randomized using a 2:1 allocation ratio to receive PnOIT or placebo for 134 weeks (2000 mg peanut protein/day) followed by 26 weeks of avoidance with participants and study staff/investigators blinded to treatment arm assignment. Desensitization at the end of treatment (week 134), as the primary outcome, and remission after avoidance (week 160), as the key secondary outcome, were assessed by DBPCFC to 5000 mg. Safety and immunological parameters were assessed. Findings. Of 146 children, with a median age of 39.3 (IQR:30.8,44.7) months, randomized from August 2013 to October 2015, 96 were assigned and analyzed in the PnOIT-treatment arm and 50 in the placebo-treatment arm. At week 134, 68/96 (71%; 95% CI:61%,80%) PnOIT-treated compared to 1/50 (2%; 95% CI:0.05%,11%) placebo-treated participants met the primary outcome of desensitization (risk difference (RD)=69%; 95% CI:59%,79%; p<0.0001). The median cumulative tolerated dose (CTD) during the week 134 DBPCFC was 5005 mg (Interquartile Range (IQR):3755,5005) for PnOIT-treated versus 5 mg (IQR:0,105) for placebo-treated (p<0.0001). After avoidance, 20/96 (21%; 95% CI:13%,30%) on PnOIT compared to 1/50 (2%; 95% CI:0.05%,11%) on placebo met remission criteria (RD:19%; 95% CI:10%,28%; p=0.0021). The median CTD during the week 160 DBPCFC was 755 mg (IQR:0,2755) for the PnOIT-treated and 0 mg (IQR:0,55) for placebo-treated (p<0.0001). A significant proportion of PnOIT participants who passed the 5000 mg DBPCFC at week 134 could no longer tolerate 5000 mg at week 160 (p<0.001). The placebo participant who was desensitized at week 134 also achieved remission at week 160. Compared to placebo treatment, peanut- and Ara h2-specific-IgE, skin prick test, and basophil activation decreased, while peanut- and Ara h2-specific-IgG4 increased in PnOIT-treated participants at weeks 134 and 160. Using multivariable regression analysis of PnOIT-treated participants, younger age and lower baseline peanut-specific IgE was predictive of remission. Most participants (98% PnOIT vs. 80% placebo) experienced at least 1 OIT dosing reaction, predominantly mild-moderate and occurring more frequently in PnOIT-treated participants; 35 OIT dosing events with moderate symptoms were treated with epinephrine in 21 PnOIT participants. Interpretation. In peanut-allergic children, initiation of PnOIT before age 4 years is associated with an increase in both desensitization and remission. Development of remission correlates with immunologic biomarkers. The outcomes suggest a window of opportunity at a young age for intervention to induce remission. Funding. National Institute of Allergy and Infectious Disease, Immune Tolerance Network Trial registration: The trial is registered on clinicaltrials.gov (NCT03345160).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sampson, H. A., Muñoz-Furlong, A., Campbell, R. L., Adkinson, N. F., Bock, S. A., Branum, A., Brown, S. G. A., Camargo, C. A., Cydulka, R., Galli, S. J., et al. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.12.1303 · Cited by 2,313
Self-citationFatalities due to anaphylactic reactions to foods
Bock, S. A., Muñoz-Furlong, A., & Sampson, H. A. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.112031 · Cited by 1,566
Self-citationThe prevalence, severity, and distribution of childhood food allergy in the United States
Gupta, R. S., Springston, E. E., Warrier, M. R., Smith, B., Kumar, R., Pongracic, J., & Holl, J. L. (2011) · PEDIATRICS · doi:10.1542/peds.2011-0204 · Cited by 1,417
AR101 Oral Immunotherapy for Peanut Allergy
The PALISADE Group of Clinical Investigators (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1812856 · Cited by 765
Oral Immunotherapy for Treatment of Egg Allergy in Children
Burks, A. W., Jones, S. M., Wood, R. A., Fleischer, D. M., Sicherer, S. H., Lindblad, R. W., Stablein, D., Henning, A. K., Vickery, B. P., Liu, A. H., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200435 · Cited by 700
Self-citationThe natural history of peanut allergy
Skolnick, H. S., Conover-Walker, M. K., Koerner, C. B., Sampson, H. A., Burks, W., & Wood, R. A. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.112129 · Cited by 611
Self-citationVarshney, P., Jones, S. M., Scurlock, A. M., Perry, T. T., Kemper, A., Steele, P., Hiegel, A., Kamilaris, J., Carlisle, S., Yue, X., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.12.1111 · Cited by 557
Self-citationTogias, A., Cooper, S. F., Acebal, M. L., Assa'ad, A., Baker, J. R., Beck, L. A., Block, J., Byrd-Bredbenner, C., Chan, E. S., Eichenfield, L. F., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.10.010 · Cited by 509
Self-citationSustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy
Vickery, B. P., Scurlock, A. M., Kulis, M., Steele, P. H., Kamilaris, J., Berglund, J. P., Burk, C., Hiegel, A., Carlisle, S., Christie, L., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.11.007 · Cited by 436
Self-citationEffect of Avoidance on Peanut Allergy after Early Peanut Consumption
Du Toit, G., Sayre, P. H., Roberts, G., Sever, M. L., Lawson, K., Bahnson, H. T., Brough, H. A., Santos, A. F., Harris, K. M., Radulovic, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1514209 · Cited by 413
Self-citation
Cited by
Allergen immunotherapy: past, present and future
Durham, S. R., & Shamji, M. H. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00786-1 · Cited by 413
Mechanisms of Allergen Immunotherapy and Potential Biomarkers for Clinical Evaluation
Sahiner, U. M., Giovannini, M., Escribese, M. M., Paoletti, G., Heffler, E., Alvaro Lozano, M., Barber, D., Canonica, G. W., & Pfaar, O. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13050845 · Cited by 66
Basophil Activation Test in the Food Allergy Clinic: Its Current Use and Future Applications
Bergmann, M. M., & Santos, A. F. (2024) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2024.2336568 · Cited by 39
Mechanisms and Biomarkers of Successful Allergen-Specific Immunotherapy
López, J.-F., Bel Imam, M., Satitsuksanoa, P., Lems, S., Yang, M., Hwang, Y.-K., Losol, P., Choi, J.-P., Kim, S.-H., Chang, Y.-S., et al. (2022) · Asia Pacific Allergy · doi:10.5415/apallergy.2022.12.e45 · Cited by 25
Nutrition and immunity: perspectives on key issues and next steps
Dunbar, C. L., Aukema, H. M., Calder, P. C., Gibson, D. L., Henrickson, S. E., Khan, S., Mailhot, G., Panahi, S., Tabung, F. K., Tom, M., et al. (2023) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2022-0276 · Cited by 24
Metadata
- Authors
- Jones, S. M., Kim, E. H., Nadeau, K. C., Nowak-Wegrzyn, A., Wood, R. A., Sampson, H. A., Scurlock, A. M., Chinthrajah, S., Wang, J., Pesek, R. D., Sindher, S. B., Kulis, M., Johnson, J., Spain, K., Babineau, D. C., Chin, H., Laurienzo-Panza, J., Yan, R., Larson, D., Qin, T., Whitehouse, D., Sever, M. L., Sanda, S., Plaut, M., Wheatley, L. M., & Burks, A. W.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2022-01
- Volume
- 399
- Issue
- 10322
- Pages
- 359-371
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4206035800
- Cited by
- 345
- References
- 27
- FWCI
- 40.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study. https://app.cochat.ai/papers/10.1016/s0140-6736(21)02390-4
- The paper
- Jones, S. M., Kim, E. H., Nadeau, K. C., Nowak-Wegrzyn, A., Wood, R. A., Sampson, H. A., Scurlock, A. M., Chinthrajah, S., Wang, J., Pesek, R. D., Sindher, S. B., Kulis, M., Johnson, J., Spain, K., Babineau, D. C., Chin, H., Laurienzo-Panza, J., Yan, R., Larson, D., . . . Burks, A. W. (2022). Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study. The Lancet. https://doi.org/10.1016/s0140-6736(21)02390-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.